✦ LIBER ✦

Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist

✍ Scribed by Pancras C. Wong; S.William Tam; William F. Herblin; Pieter B.M.W.M. Timmermans

Book ID: 115886947
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 440 KB
Volume: 196
Category: Article
ISSN: 0014-2999
DOI: 10.1016/0014-2999(91)90429-t

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proximal nephron and renal effects of Du

Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist

✍ Xie, Ming-Hong; Liu, Fu-Ying; Wong, Pancras C; Timmermans, Pieter B M W M; Cogan 📂 Article 📅 1990 🏛 Nature Publishing Group 🌐 English ⚖ 646 KB

Effect of a nonpeptide angiotensin II re

Effect of a nonpeptide angiotensin II receptor antagonist, DuP 753, on angiotensin-related water intake in rats

✍ Fregly, Melvin J.; Rowland, Neil E. 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 519 KB

DuP 753, a nonpeptide angiotensin II-1 r

DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum

✍ L. P. Dwoskin; A. L. Jewell; L. A. Cassis 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 838 KB

Pharmacology of an active metabolite of

Pharmacology of an active metabolite of DuP 753 — an orally-active nonpeptide angiotensin II receptor antagonist

✍ P.B.M.W.M. Timmermans; P.C. Wong; W.A. Price; A.T. Chiu; J.V. Duncia; D.J. Carin 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 93 KB

DuP 532: A second generation of nonpepti

DuP 532: A second generation of nonpeptide angiotensin II receptor antagonists

✍ Andrew T. Chiu; David J. Carini; John V. Duncia; Kam H. Leung; Dale E. McCall; W 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 636 KB

Pilot study of the uricosuric effect of

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

✍ M. Nakashima; T. Uematsu; K. Kosuge; M. Kanamaru 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 341 KB

The uricosuric effect of DuP-753, a novel, specific angiotensin II receptor antagonist, has been explored in a healthy male Japanese volunteers, given single oral doses of 25, 50, 100 or 200 mg (n = 6), or 100 mg (n = 6) or placebo (n = 3) once daily for 7 consecutive days. In the single-dose study,